Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide and Abiraterone in CRPC (BARRIER-P)
NCT02429193Phase 2Completed
- Sponsor
- University Health Network
- Start
- Mar 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide, abiraterone in castration-resistant prostate cancer (CRPC), sponsored by University Health Network. Started Mar 2016; status: completed.
02
Drugs
enzalutamideabiraterone
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02429193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02429193.